Epidemiologist Erin Bowles, MPH, is looking at cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Health Care Systems Cancer Research Network (CRN) — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of care in cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20 years has provided her with expertise in data collection and quality control for many subject areas. She is also a manager of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to junior faculty.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Bowles EA, Feigelson HS, Sterrett A, Barney T, Broecker K, Bischoff K, Engel J, Gundersen G, James T, Onitilo A, McCahill L. Improving quality of breast cancer surgery through development of a national breast cancer surgical outcomes database. Clin Med Res. 2011;9(3-4):144. PubMed
Delate T, Bowles E, Pardee R, Wellman R, Habel L, Yood M, Nekhlyudov L, Goddard K, Davis R, McCarty C, Onitilo A, Feigelson H, Freml J, Wagner E. Validity of HMO administrative data for breast cancer chemotherapy exposure. Clin Med Res. 2011;9(3-4):146. PubMed
Bowles EA, Wellman R, Delate T, Allen L, Feigelson HS, Yood MU, Davis R, Nekhlyudov L, McCarty C, Habel L, Magid D, Onitilo A, Freedman A, Wagner E. Cardiotoxic chemotherapy is associated with increased heart failure risk among women with breast cancer in the Cancer Research Network. Clin Med Res. 2011;9(3-4):148. PubMed
Lowry S, Aiello Bowles EJ, Anderson ML, Buist DS. Predictors of breast density change after hormone therapy cessation: results from the READ randomized trial. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2309-12. Epub 2011 Aug 3. PubMed
Carney PA, Cook AJ, Miglioretti DL, Feig SA, Bowles EA, Geller BM, Kerlikowske K, Kettler M, Onega T, Elmore JG. Use of clinical history affects accuracy of interpretive performance of screening mammography. J Clin Epidemiol. 2012 Feb;65(2):219-30. Epub 2011 Oct 15. PubMed
Tom SE, Anderson ML, Landis CA, Aiello Bowles EJ, Woods NF, Reed SD, Newton KM, Buist DS. Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial. Menopause. 2011 Nov;18(11):1184-90. PubMed
The division contributes to research across the institute with methodological and subject matter expertise.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease.
Study suggests disparities at screening sites may influence lag in follow-ups.